The Short Answer
Incyte stock (INCY) is doubtful under the current filing-based screen for Muslim investors. Incyte is a commercial-stage biopharmaceutical company that discovers, develops, and markets therapies in oncology, hematology, and inflammation and autoimmunity, anchored by its JAK-inhibitor franchise. Developing and selling medicines is generally permissible, but the current liquidity and receivables screens fail.
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
0 / 7,339.113
4,015.825 / 7,339.113
4,512.613 / 7,339.113
33.687 / 1,272.676
- Financial
- Fails
- Overall
- Fails
Debt/assets is 0.00%, but liquidity/assets is 54.72% and receivables plus cash/assets is 61.49%, above the examined FTSE limits; interest income/revenue is 2.65%.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 54.72% and receivables plus cash/assets is 61.49%, above the examined MSCI total-assets limits; debt/assets is 0.00% and interest income/revenue is 2.65%.
- Financial
- Fails
- Overall
- Fails
Identifiable liquidity/assets is 54.72%, above the examined Malaysia SAC limit; debt/assets is 0.00%. This is not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; the asset-based screens fail on liquidity and receivables-plus-cash.
Business-activity disclosure
Incyte develops and markets oncology, hematology, inflammation and autoimmune therapies. Prescription medicines are generally permissible, while product, collaboration and end-use disclosures require continuing review.
Limitation: The filing does not allocate every product, collaboration or pipeline revenue stream into a universal prohibited-activity numerator.
Purification
Incyte discloses $33.687 million of investment income interest, but no scholar-approved purification percentage is inferred.
Inputs, assumptions and primary sources
- Amounts are USD millions from Incyte's March 31, 2026 Form 10-Q.
- No interest-bearing debt is identified in the extracted balance-sheet facts; operating leases are excluded.
- Cash and cash equivalents are $3,461.114 million. Available-for-sale debt securities are $554.711 million and are included as identifiable interest-bearing securities.
- Accounts receivable, net is $1,051.499 million and first-quarter revenue is $1,272.676 million.
- Investment income interest is $33.687 million; the filing does not provide a universal prohibited-revenue numerator for every medicine, collaboration or customer end use.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Incyte has no identified interest-bearing debt, but the March 31, 2026 filing shows liquidity/assets of 54.72% and receivables-plus-cash/assets of 61.49%, above the examined asset-based limits. Investment income interest is 2.65% of first-quarter revenue.
Sharia Screening Methodology
Islamic scholars use several criteria to screen stocks:
- Business activity screen: Is the company's primary business halal?
- Debt ratio: Total debt / market cap must be under 33%
- Interest income: Interest income / total revenue must be under 5%
- Haram revenue: Revenue from haram sources must be under 5%
- Receivables ratio: Total receivables / total assets must be under 49–70% (varies by board)
What Incyte Does
Incyte Corporation (headquartered in Wilmington, Delaware) develops and markets targeted therapies across several areas:
- Oncology and hematology: Its JAK-inhibitor franchise and other cancer therapies.
- Inflammation and autoimmunity: Dermatology and immune-mediated disease treatments.
- Pipeline: A broad research pipeline of small molecules and biologics.
Developing and selling medicines is a permissible activity, so the business-activity screen passes cleanly.
Why It Passes (and What to Check)
1. Permissible Core Business
Incyte's revenue comes from prescription therapies that treat cancer and immune-mediated diseases — a clearly permissible activity. There is no haram revenue line.
2. Low Debt (Strong Screen)
Incyte carries very little debt and a large cash position, so the total-debt-to-market-cap screen is comfortably within the 33% threshold. Still, confirm the debt and receivables ratios against the latest filings.
3. Interest Income (Purify)
Incyte's March 31, 2026 filing reports $33.687 million of investment income interest, or 2.65% of first-quarter revenue. The corresponding purification treatment depends on the scholar or methodology followed.
Financial Ratios
Based on Incyte's March 31, 2026 Form 10-Q (USD millions):
- Debt / Assets: 0.00% — no identified interest-bearing debt ✅
- Liquidity / Assets: 54.72% — above the examined 33.333% limit ❌
- Receivables + Cash / Assets: 61.49% — above the examined limits ❌
- Investment income interest / Revenue: 2.65% disclosed ✅/⚠️
The current asset-based result fails on liquidity and receivables-plus-cash despite zero identified debt. Pharmaceutical activity remains generally permissible, but the quantitative result is doubtful.
What About Purification?
Incyte discloses investment income interest, but this page does not infer a scholar-approved purification percentage. The asset-based screen also fails independently on liquidity and receivables-plus-cash.
Methodology Interpretation
The current filing-based asset screen fails on liquidity and receivables-plus-cash. Business activity, market-cap denominators, security classification and purification remain methodology-dependent. This is a ZakatInvest analysis, not an official index or agency classification.
Bottom Line
Incyte (INCY) is doubtful for Muslim investors under the current filing-based asset screen. The oncology-and-inflammation medicine business is generally permissible and debt is not identified, but liquidity/assets of 54.72% and receivables-plus-cash/assets of 61.49% exceed the examined limits. Re-screen after the next filing and follow the methodology a reader uses.
Want to check if another stock is halal? Use our free screener.
Open Halal Checker →